Clinical Role - Specialty Pharmacy
Pharmacy Times® is a leader in providing expert insights and clinical updates to specialty pharmacists and reaches more than 200,000 pharmacy professionals in total.
In a session at the American Society of Hematology Annual Meeting and Exposition, held December 7-10 in Orlando, Florida, experts presented on the evolution of CLL therapy, how to make treatment decisions, and what’s to come in the future based on ongoing studies.
Jennifer Woyach, MD, associate professor at The Ohio State University, gives an overview of the new data in chronic lymphocytic leukemia being presented at the 2019 American Society of Hematology Annual Meeting and Exposition.
The study evaluated lymphoma characteristics and outcomes in hepatitis C virus-associated B-cell non-Hodgkin lymphoma in African American patients.
A novel, off-the-shelf bispecific antibody could serve as a new treatment option for patients with non-Hodgkin lymphoma who don’t respond to CAR T-cell therapy.
Jennifer Woyach, MD, associate professor at The Ohio State University, explains how patient-specific factors can help determine treatment decisions in chronic lymphocytic leukemia.
A study looked at adherence rates and potential predictors of nonadherence in patients with hemophilia receiving emicizumab.
The analysis evaluated emerging mutations in patients with relapsed/refractory acute myeloid leukemia receiving gilteritinib therapy in the phase 3 ADMIRAL study.
A prospective analysis of the CLL14 trial showed that fixed-duration treatment of venetoclax plus obinutuzumab achieved high rates of undetectable minimal residual disease.
Jennifer Woyach, MD, associate professor at The Ohio State University, discusses current clinical trials going on in the chronic lymphocytic leukemia space that are most likely to impact the treatment landscape.
Patients receiving novel oral therapeutics often have a high dependence on financial assistance; specialty pharmacies may help facilitate access to these therapies.
A discussion on when to implement bevacizumab into the treatment plan and the rationale for using PARP inhibitors to treat individuals with ovarian cancer.
Top articles of the week from Specialty Pharmacy Times.